We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-4.56%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$206M
AUM Growth
-$197M
Cap. Flow
-$141M
Cap. Flow %
-68.56%
Top 10 Hldgs %
61.73%
Holding
47
New
9
Increased
7
Reduced
14
Closed
15

Top Buys

Rank Stock Value
1
GYRE icon
Gyre Therapeutics
GYRE
+$8.48M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$8.06M
3
VSTM icon
Verastem
VSTM
+$7.78M
4
BTAI icon
BioXcel Therapeutics
BTAI
+$7.08M
5
MRSN
Mersana Therapeutics
MRSN
+$5.78M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$24.4M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$20.1M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$15.8M
4
ARWR icon
Arrowhead Research
ARWR
+$13.4M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 93.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNS
26
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.11M 1.02%
+259,500
New +$2.25M
GBT
27
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.99M 0.97%
+39,000
New +$2.61M
KURA icon
28
Kura Oncology
KURA
$850M
$1.97M 0.95%
198,000
-42,000
-18% -$481K
LRMR icon
29
Larimar Therapeutics
LRMR
$432M
$1.07M 0.52%
115,500
+32,167
+39% +$423K
BCRX icon
30
BioCryst Pharmaceuticals
BCRX
$2.4B
$500K 0.24%
250,000
-2,575,000
-91% -$7.09M
ISEE
31
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$478K 0.23%
139,000
-771,000
-85% -$4.51M
ABUS icon
32
Arbutus Biopharma
ABUS
$915M
$273K 0.13%
+269,907
New +$730K
ADVM
33
CALL
DELISTED
Adverum Biotechnologies
ADVM
– –
-10,000
Closed -$1.15M
INSM icon
34
Insmed
INSM
$28.6B
– –
-169,000
Closed -$4.04M
KALV
35
DELISTED
KalVista Pharmaceuticals
KALV
– –
-107,500
Closed -$1.92M
KPTI icon
36
Karyopharm Therapeutics
KPTI
$48M
– –
-39,333
Closed -$11.3M
MIST icon
37
Milestone Pharmaceuticals
MIST
$152M
– –
-508,500
Closed -$8.14M
NGNE icon
38
Neurogene
NGNE
$712M
– –
-18,625
Closed -$4.59M
XBI icon
39
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-500,000
Closed -$47.6M
XFOR icon
40
X4 Pharmaceuticals
XFOR
$460M
– –
-1,333
Closed -$428K
ZYME icon
41
Zymeworks
ZYME
$1.67B
– –
-70,500
Closed -$3.21M
GRCE
42
Grace Therapeutics
GRCE
$34.7M
– –
-12,917
Closed -$1.52M
ITCI
43
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-100,000
Closed -$3.43M
ITCI
44
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-587,089
Closed -$20.1M
CCXI
45
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-35,000
Closed -$1.38M
IMMU
46
DELISTED
Immunomedics Inc
IMMU
– –
-150,000
Closed -$3.17M
MDCO
47
DELISTED
Medicines Co
MDCO
– –
-21,700
Closed -$1.84M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q1 2020 Portfolio in Review

As of Q1 2020, Acuta Capital Partners held 47 positions worth $206M, down 49% from $404M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Acuta Capital Partners withdrew a net $141M in Q1 2020, closing 15 positions and reducing 14 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $20.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 83% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in Gyre Therapeutics worth $6.05M.

  • Acuta Capital Partners's largest Q1 2020 buy was Gyre Therapeutics: 184,613 shares worth $6.05M.
  • Acuta Capital Partners added most to Avadel Pharmaceuticals in Q1 2020, an estimated $8.06M increase.
  • Acuta Capital Partners's biggest Q1 2020 reduction was Axsome Therapeutics, cutting an estimated $24.4M.
  • Acuta Capital Partners fully exited Intra-Cellular Therapies Inc. in Q1 2020, selling an estimated $20.1M.
  • Acuta Capital Partners's ten largest holdings make up 62% of its $206M portfolio in Q1 2020.
  • Acuta Capital Partners opened 9 new positions and closed 15 in Q1 2020.
  • Acuta Capital Partners's portfolio value fell 49% quarter-over-quarter to $206M.

Based on Acuta Capital Partners's 13F filing for Q1 2020, filed 15 May 2020.